BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28099264)

  • 21. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
    Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G
    Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative value of ultrasound, computed tomography and positron emission tomography imaging in the clinically node-negative neck in oral cancer.
    Chaukar D; Dandekar M; Kane S; Arya S; Purandare N; Rangarajan V; Deshmukh A; Pai P; Chaturvedi P; D'Cruz A
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):e332-8. PubMed ID: 25131685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
    J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma.
    Bird T; Barrington S; Thavaraj S; Jeannon JP; Lyons A; Oakley R; Simo R; Lei M; Guerrero Urbano T
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1239-47. PubMed ID: 26707387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma.
    Cheng NM; Fang YH; Chang JT; Huang CG; Tsan DL; Ng SH; Wang HM; Lin CY; Liao CT; Yen TC
    J Nucl Med; 2013 Oct; 54(10):1703-9. PubMed ID: 24042030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.
    Schramm N; Rominger A; Schmidt C; Morelli JN; Schmid-Tannwald C; Meinel FG; Reiser MF; Rist C
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1014-24. PubMed ID: 23503574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.
    Ong SC; Schöder H; Lee NY; Patel SG; Carlson D; Fury M; Pfister DG; Shah JP; Larson SM; Kraus DH
    J Nucl Med; 2008 Apr; 49(4):532-40. PubMed ID: 18344440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary vs nodal site PET/CT response as a prognostic marker in oropharyngeal squamous cell carcinoma treated with intensity-modulated radiation therapy.
    Eckstein JM; Nolan N; Healy E; Wright CL; Jain A; Barney CL; Washington I; McElroy JP; Grecula JC; Wobb JL; Mitchell DL; Miller E; Gamez M; Blakaj D; Diavolitsis V; Bhatt A
    Head Neck; 2020 Sep; 42(9):2405-2413. PubMed ID: 32391626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Performance of Response Assessment FDG-PET/CECT in HNSCC Treated With Definitive Radio(chemo)therapy Using NI-RADS.
    Paul S; Gupta T; Purandare N; Joshi K; Ghosh-Laskar S; Budrukkar A; Swain M; Sinha S; Kumar A; Joshi A; Prabhash K; Nair S; Rangarajan V; Agarwal JP
    Otolaryngol Head Neck Surg; 2023 Oct; 169(4):938-947. PubMed ID: 36856038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma.
    Lu P; Sun Y; Sun Y; Yu L
    Lung Cancer; 2014 Jul; 85(1):53-8. PubMed ID: 24792334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of Likert scale (Deauville criteria) in assessment of Chemoradiotherapy response of primary oropharyngeal squamous cell Cancer site.
    Koksel Y; Gencturk M; Spano A; Reynolds M; Roshan S; Caycı Z
    Clin Imaging; 2019; 55():89-94. PubMed ID: 30771643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma.
    Chan JY; Sanguineti G; Richmon JD; Marur S; Gourin CG; Koch W; Chung CH; Quon H; Bishop JA; Aygun N; Agrawal N
    Arch Otolaryngol Head Neck Surg; 2012 Nov; 138(11):1040-6. PubMed ID: 23165378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer.
    Driscoll DO; Halpenny D; Johnston C; Sheehy N; Keogan M
    Abdom Imaging; 2015 Jan; 40(1):127-33. PubMed ID: 25015401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of FDG PET/Contrast-Enhanced CT in Initial Staging of Colorectal Cancer - Comparison with Contrast-Enhanced CT.
    Kunawudhi A; Sereeborwornthanasak K; Promteangtrong C; Siripongpreeda B; Vanprom S; Chotipanich C
    Asian Pac J Cancer Prev; 2016; 17(8):4071-5. PubMed ID: 27644663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma: A Review.
    Taghipour M; Sheikhbahaei S; Marashdeh W; Solnes L; Kiess A; Subramaniam RM
    JAMA Otolaryngol Head Neck Surg; 2016 Jan; 142(1):79-85. PubMed ID: 26583955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
    Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H
    Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.